FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.

about

FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q52627284

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

FOLFIRI plus panitumumab in th ...... metastatic colorectal cancer.

@en

FOLFIRI plus panitumumab in th ...... metastatic colorectal cancer.

@nl

type

Item

label

FOLFIRI plus panitumumab in th ...... metastatic colorectal cancer.

@en

FOLFIRI plus panitumumab in th ...... metastatic colorectal cancer.

@nl

prefLabel

FOLFIRI plus panitumumab in th ...... metastatic colorectal cancer.

@en

FOLFIRI plus panitumumab in th ...... metastatic colorectal cancer.

@nl

P1476

FOLFIRI plus panitumumab in th ...... metastatic colorectal cancer.

@en

P2093

Caglayan Geredeli

http://www.w3.org/2001/XMLSchema#string

Nurgul Yasar

http://www.w3.org/2001/XMLSchema#string

P2860

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS stat

Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis.

Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

NCCN Clinical Practice Guidelines in Oncology: colon cancer.

P2888

s12957-018-1359-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12957-018-1359-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1101768535

http://www.w3.org/2001/XMLSchema#string

P698

29587749

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5870197

http://www.w3.org/2001/XMLSchema#string